Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation

During the last decade, the use of tyrosine kinase inhibitor (TKI) therapy has modified the natural history of chronic myeloid leukemia (CML) allowing an increase of the overall and disease-free survival, especially in patients in whom molecular residual disease becomes undetectable. However, it has...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Chomel, Jean Claude, Bonnet, Marie Laure, Sorel, Nathalie, Sloma, Ivan, Bennaceur-Griscelli, Annelise, Rea, Delphine, Legros, Laurence, Marfaing-Koka, Anne, Bourhis, Jean-Henri, Ame, Shanti, Guerci-Bresler, Agnès, Rousselot, Philippe, Turhan, Ali G.
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2016
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5085229/
https://ncbi.nlm.nih.gov/pubmed/27167108
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.9182
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars